ERIC KINSMAN: Open Payments
NPI 1619225083 · FORT POLK, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$411 in 17 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $515 · 2025 $411
Food & beverage: $411
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 7 | $178 |
| E.R. Squibb & Sons, L.L.C. | 2 | $47 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $44 |
| Lundbeck LLC | 1 | $29 |
| Teva Pharmaceuticals USA, Inc. | 1 | $28 |
| ABBVIE INC. | 1 | $23 |
| Neurocrine BioSciences, Inc. | 1 | $21 |
| Alkermes, Inc. | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $20 |
Products named: REXULTI, COBENFY, CAPLYTA, AUSTEDO XR, VRAYLAR, INGREZZA, ARISTADA, Auvelity.
Industry payments across LA — which companies pay providers there.
